Pharming Group N.V. Files 2025 Annual Report and Form 20-F

On April 2, 2026, Pharming Group N.V. announced the filing of its Annual Report for the fiscal year ended December 31, 2025. The company also confirmed the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The reports, which provide comprehensive details on the company's financial performance and operations for the 2025 period, are available on the company's website and the SEC's EDGAR database. Pharming is a global biopharmaceutical company focused on developing and commercializing therapies for rare and life-threatening diseases, including small molecules and biologics. This filing is a routine regulatory requirement for foreign private issuers listed on U.S. exchanges and does not contain new clinical data or immediate material changes to corporate strategy. All financial documents are accessible via the company's investor relations portal.